Despite some states offering limited coverage of GLP-1s to treat weight loss as far back as a decade ago, most states that currently provide coverage through taxpayer-funded Medicaid programs or state employee health plans have only opted to do so within the past five years
Its prevalence varies significantly due to factors such as geographic location, regional differences, ethnicity, dietary habits, and economic conditions
Chemical Properties Molecular Formula: C225H348N48O68 Molecular Weight: 4813.45 g/mol CAS Number: 2023788-19-2 IUPAC / Code Name: LY-3298176 Synonyms: Tirzepatide, LY3298176, OYN3CCI6QE Mechanism of Action is engineered to interact with both: glucose-dependent insulinotropic polypeptide (GIP) receptor glucagon-like peptide-1 (GLP-1) receptor This dual activity makes it different from single-pathway peptides
The most common is subcutaneous injection from a reconstituted vial
This slow progression reduces side effects and allows the body to adjust to the combination of bupropion and naltrexone
However, a crucial limitation of the above studies is that the endpoint was pathologic (described as asymptomatic chronic pancreatitis), referring to histologic changes, rather than clinical 26